217 related articles for article (PubMed ID: 32980659)
21. Intensity-modulated radiotherapy for elderly patients with nasopharyngeal carcinoma.
Cao C; Hu Q; Chen X
Head Neck; 2018 Mar; 40(3):590-595. PubMed ID: 29155480
[TBL] [Abstract][Full Text] [Related]
22. 10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma.
Chen L; Zhang Y; Lai SZ; Li WF; Hu WH; Sun R; Liu LZ; Zhang F; Peng H; Du XJ; Lin AH; Sun Y; Ma J
Oncologist; 2019 Jan; 24(1):e38-e45. PubMed ID: 30082487
[TBL] [Abstract][Full Text] [Related]
23. Incidence and Demographics of Nasopharyngeal Carcinoma in Cheung Chau Island of Hong Kong-A Distinct Geographical Area With Minimal Residential Mobility and Restricted Public Healthcare Referral Network.
Chan SK; Chau SC; Chan SY; Tong CC; Lam KO; Lai-Wan Kwong D; Leung TW; Luk MY; Lee AW; Choi HC; Lee VH
Cancer Control; 2021; 28():10732748211047117. PubMed ID: 34565216
[TBL] [Abstract][Full Text] [Related]
24. Dosimetric parameters associated with conductive or sensorineural hearing loss 5 years after intensity-modulated radiation therapy in nasopharyngeal carcinoma.
Zhu W; Chen F; Li J; Wang W; Zhang H; Yang G; Zou L; Zhu Y; Yuan W; Ding H; Song X; Wang S
Acta Otolaryngol; 2019 Mar; 139(3):263-268. PubMed ID: 30870056
[TBL] [Abstract][Full Text] [Related]
25. Stage-dependent conditional survival and failure hazard of non-metastatic nasopharyngeal carcinoma after intensity-modulated radiation therapy: Clinical implications for treatment strategies and surveillance.
Wang J; Huang X; Sun S; Wang K; Qu Y; Chen X; Wu R; Zhang Y; Liu Q; Zhang J; Luo J; Xiao J; Gao L; Xu G; Hu C; Li YX; Yi J
Cancer Med; 2021 Jun; 10(11):3613-3621. PubMed ID: 33960136
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma.
Hu J; Huang Q; Gao J; Guan X; Hu W; Yang J; Qiu X; Chen M; Kong L; Lu JJ
Cancer; 2020 Dec; 126(23):5173-5183. PubMed ID: 32931035
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy: A meta-analysis.
Leong YH; Soon YY; Lee KM; Wong LC; Tham IWK; Ho FCH
Head Neck; 2018 Mar; 40(3):622-631. PubMed ID: 29130584
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome and pattern of failure for patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.
Tian YM; Liu MZ; Zeng L; Bai L; Lin CG; Huang SM; Deng XW; Chong-Zhao ; Lu TX; Han F
Head Neck; 2019 May; 41(5):1246-1252. PubMed ID: 30593728
[TBL] [Abstract][Full Text] [Related]
29. Postirradiation otitis media with effusion in nasopharyngeal carcinoma patients treated by intensity-modulated radiotherapy.
Hsin CH; Chen TH; Liang KL; Tseng HC; Liu WS
Laryngoscope; 2013 Sep; 123(9):2148-53. PubMed ID: 23835775
[TBL] [Abstract][Full Text] [Related]
30. Clinical course of longer than five years after definitive radiotherapy for nasopharyngeal carcinoma.
Doi H; Ri A; Inada M; Tatsuno S; Uehara T; Matsuura T; Ishikawa K; Nakamatsu K; Hosono M; Nishimura Y
Int J Clin Oncol; 2023 Dec; 28(12):1607-1615. PubMed ID: 37798414
[TBL] [Abstract][Full Text] [Related]
31. Irradiation-induced nasopharyngeal necrosis (INN) in newly diagnosed nasopharyngeal carcinoma treated by intensity-modulated radiation therapy: clinical characteristics and the influence of treatment strategies.
Xu Y; Liu Y; Wang Z; Wang J; Zhang J; Chen X; Wu R; Liu Q; Qu Y; Wang K; Huang X; Luo J; Gao L; Xu G; Zhang Y; Yi J
Radiat Oncol; 2022 Jan; 17(1):13. PubMed ID: 35062991
[TBL] [Abstract][Full Text] [Related]
32. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
[TBL] [Abstract][Full Text] [Related]
34. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y
Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002
[TBL] [Abstract][Full Text] [Related]
35. Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma.
Liu YP; Lv X; Zou X; Hua YJ; You R; Yang Q; Xia L; Guo SY; Hu W; Zhang MX; Chen SY; Lin M; Xie YL; Liu LZ; Sun R; Huang PY; Fan W; Guo X; Hong MH; Chen MY
Cancer Commun (Lond); 2019 Nov; 39(1):75. PubMed ID: 31730020
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes and failure patterns of patients with nasopharyngeal carcinoma staged by magnetic resonance imaging in intensity-modulated radiotherapy era: The Zhejiang Cancer Hospital's experience.
Jiang F; Jin T; Feng XL; Jin QF; Chen XZ
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C179-84. PubMed ID: 26506872
[TBL] [Abstract][Full Text] [Related]
37. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
Fangzheng W; Chuner J; Haiyan Q; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Peng W; Kaiyuan S; Zhenfu F; Yangming J
Medicine (Baltimore); 2019 Dec; 98(51):e18484. PubMed ID: 31861031
[TBL] [Abstract][Full Text] [Related]
38. A Multicentre UK Study of Outcomes of Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy ± Chemotherapy.
Slevin F; Pan S; Mistry H; Sen M; Foran B; Slevin N; Dixon L; Thomson D; Prestwich R
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):238-249. PubMed ID: 31813661
[TBL] [Abstract][Full Text] [Related]
39. Advances in radiotherapy and its impact on second primary cancer risk: A multi-center cohort study in prostate cancer patients.
Jahreiß MC; Hoogeman M; Aben KK; Dirkx M; Snieders R; Pos FJ; Janssen T; Dekker A; Vanneste B; Minken A; Hoekstra C; Smeenk RJ; Incrocci L; Heemsbergen WD
Radiother Oncol; 2023 Jun; 183():109659. PubMed ID: 37003369
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
